Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
US-11679075-B2 · Jun 20, 2023 · US
Methods for treating Parkinson's disease by administering resiniferatoxin
US12201608B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12201608-B2 |
| Application number | US-202117345641-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 11, 2021 |
| Priority date | Dec 24, 2018 |
| Publication date | Jan 21, 2025 |
| Grant date | Jan 21, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
There is disclosed a method for treating Parkinson's Disease (PD) comprising administering an effective amount of Resiniferatoxin (RTX) by an intrathecal or intracisternal administration. In some embodiments, the dose of RTX for an adult human is from about 0.1 μg to about 100 μg.
First claim
Opening claim text (preview).
We claim: 1. A method for treating Parkinson's Disease (PD) comprising administering to a subject in need of treatment for PD an effective amount of Resiniferatoxin (RTX) intrathecally or intracisternally. 2. The method of claim 1 , wherein the subject is an adult human. 3. The method of claim 1 , wherein the RTX is administered in a dose of from about 0.1 μg to about 100 μg. 4. The method of claim 3 , wherein the dose is from about 0.1 μg to about 1 μg, about 1 μg to about 5 μg, about 5 μg to about 10 μg, about 10 μg, to about 20 μg, about 20 μg to about 50 μg, or about 50 to about 100 μg. 5. The method of claim 1 , wherein the method comprises intrathecal administration. 6. The method of claim 1 , wherein the method comprises intracisternal administration. 7. The method of claim 1 , wherein the RTX is administered in a pharmaceutical formulation comprising the RTX and a pharmaceutically acceptable carrier. 8. The method of claim 7 , wherein the pharmaceutically acceptable carrier comprises water. 9. The method of claim 7 , wherein the pharmaceutically acceptable carrier comprises saline. 10. The method of claim 7 , wherein the RTX is present in the pharmaceutical formulation at a concentration ranging from 1 μg/ml to 100 μg/ml. 11. The method of claim 10 , wherein the RTX is present in the pharmaceutical formulation at a concentration ranging from 1 μg/ml to 5 μg/ml, 5 μg/ml to 10 μg/ml, 10 μg/ml to 20 μg/ml, 20 μg/ml to 50 μg/ml, or 50 μg/ml to 100 μg/ml.
Assignees
Inventors
Classifications
- A61K9/0019Primary
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Anti-Parkinson drugs · CPC title
Brain, e.g. brain implants; Spinal cord · CPC title
Solutions {(composition of solutions A61K47/00)} · CPC title
- A61K31/357Primary
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12201608B2 cover?
- There is disclosed a method for treating Parkinson's Disease (PD) comprising administering an effective amount of Resiniferatoxin (RTX) by an intrathecal or intracisternal administration. In some embodiments, the dose of RTX for an adult human is from about 0.1 μg to about 100 μg.
- Who is the assignee on this patent?
- Sorrento Therapeutics Inc, Vivasor Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K9/0019. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).